Skip to Main Content

Paper Details

Safety, Feasibility, and Merits of Longitudinal Molecular Testing of Multiple Metastatic Sites to Inform mTNBC Patient Treatment in the Intensive Trial of Omics in Cancer.
JCO Precis Oncol
1
2022
Cancer, ITOMIC, Patient, Patients, RNA, cancer, cancer-associated gene panel, carcinoma of unknown primary site, cisplatin, estrogen, estrogen receptor, human, human epidermal growth factor receptor 2, lung cancer, mTNBC, metastatic triple-negative breast cancer, nonbreast cancers, patient, patients, tumor
Author NameAffiliation
Michael O DorschnerUniversity of Washington
Michael O DorschnerCenter for Precision Diagnostics, University of Washington
Michael O DorschnerUniversity of Washington
Michael O DorschnerUniversity of Washington
Michael O DorschnerUniversity of Washington
Michael O DorschnerCenter for Precision Diagnostics, University of Washington
Colin C PritchardUniversity of Washington
Brigham H Mecham
Jingchun ZhuUniversity of California at Santa Cruz
Jingchun ZhuUniversity of California at Santa Cruz
Eric P Kaldjian
Janusz Dutkowski
Carl Anthony BlauCenter for Cancer Innovation, University of Washington
Carl Anthony BlauInstitute for Stem Cell and Regenerative Medicine, University of Washington
Carl Anthony BlauUniversity of Washington
Carl Anthony Blau
  • 1 - 16

Datasets

Release 1.2